The application of dendritic cells vaccination in malignant glioma
Glioblastoma (GBM) is the most common and fatal primary adult brain tumor. To date,various promising chemotherapeutic regimens have been trialed for use in GBM; however, temozolomide(TMZ) therapy remains the only first ⁃ line chemotherapeutic option for newly diagnosed GBM. Despitemaximal therapy wi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Tianjin Huanhu Hospital
2020-02-01
|
| Series: | Chinese Journal of Contemporary Neurology and Neurosurgery |
| Subjects: | |
| Online Access: | http://www.cjcnn.org/index.php/cjcnn/article/view/2092 |
| _version_ | 1818175325195993088 |
|---|---|
| author | Hong⁃yu LIU Shao⁃ping SHEN Lin YANG Xin⁃guang YU Ling CHEN |
| author_facet | Hong⁃yu LIU Shao⁃ping SHEN Lin YANG Xin⁃guang YU Ling CHEN |
| author_sort | Hong⁃yu LIU |
| collection | DOAJ |
| description | Glioblastoma (GBM) is the most common and fatal primary adult brain tumor. To date,various promising chemotherapeutic regimens have been trialed for use in GBM; however, temozolomide(TMZ) therapy remains the only first ⁃ line chemotherapeutic option for newly diagnosed GBM. Despitemaximal therapy with surgery and combined concurrent radiotherapy and chemotherapy, and adjuvant TMZtherapy, the median overall survival (OS) remains approximately 14.6 months. Given the failure ofconventional chemotherapeutic strategies in GBM, there has been renewed interest in the role ofimmunotherapy in GBM. Dendritic cells (DC) are immune antigen⁃presenting cell (APC) that play a role inboth the innate and adaptive immune system, thereby making them prime vehicles for immunotherapy viaDC vaccinations in various cancers. There is great enthusiasm surrounding the use of vaccinations for GBMwith multiple ongoing trials. In this review, we summarize the progress, prospects and challenges of DCvaccine in the treatment of GBM.
DOI：10.3969/j.issn.1672⁃6731.2020.02.008 |
| first_indexed | 2024-12-11T19:58:30Z |
| format | Article |
| id | doaj.art-f752a3d8aa1940a8ab40a416786b8dd7 |
| institution | Directory Open Access Journal |
| issn | 1672-6731 |
| language | English |
| last_indexed | 2024-12-11T19:58:30Z |
| publishDate | 2020-02-01 |
| publisher | Tianjin Huanhu Hospital |
| record_format | Article |
| series | Chinese Journal of Contemporary Neurology and Neurosurgery |
| spelling | doaj.art-f752a3d8aa1940a8ab40a416786b8dd72022-12-22T00:52:35ZengTianjin Huanhu HospitalChinese Journal of Contemporary Neurology and Neurosurgery1672-67312020-02-012021191262047The application of dendritic cells vaccination in malignant gliomaHong⁃yu LIUShao⁃ping SHENLin YANGXin⁃guang YULing CHENGlioblastoma (GBM) is the most common and fatal primary adult brain tumor. To date,various promising chemotherapeutic regimens have been trialed for use in GBM; however, temozolomide(TMZ) therapy remains the only first ⁃ line chemotherapeutic option for newly diagnosed GBM. Despitemaximal therapy with surgery and combined concurrent radiotherapy and chemotherapy, and adjuvant TMZtherapy, the median overall survival (OS) remains approximately 14.6 months. Given the failure ofconventional chemotherapeutic strategies in GBM, there has been renewed interest in the role ofimmunotherapy in GBM. Dendritic cells (DC) are immune antigen⁃presenting cell (APC) that play a role inboth the innate and adaptive immune system, thereby making them prime vehicles for immunotherapy viaDC vaccinations in various cancers. There is great enthusiasm surrounding the use of vaccinations for GBMwith multiple ongoing trials. In this review, we summarize the progress, prospects and challenges of DCvaccine in the treatment of GBM. DOI：10.3969/j.issn.1672⁃6731.2020.02.008http://www.cjcnn.org/index.php/cjcnn/article/view/2092gliomadendritic cellscancer vaccinesimmunotherapyreview |
| spellingShingle | Hong⁃yu LIU Shao⁃ping SHEN Lin YANG Xin⁃guang YU Ling CHEN The application of dendritic cells vaccination in malignant glioma Chinese Journal of Contemporary Neurology and Neurosurgery glioma dendritic cells cancer vaccines immunotherapy review |
| title | The application of dendritic cells vaccination in malignant glioma |
| title_full | The application of dendritic cells vaccination in malignant glioma |
| title_fullStr | The application of dendritic cells vaccination in malignant glioma |
| title_full_unstemmed | The application of dendritic cells vaccination in malignant glioma |
| title_short | The application of dendritic cells vaccination in malignant glioma |
| title_sort | application of dendritic cells vaccination in malignant glioma |
| topic | glioma dendritic cells cancer vaccines immunotherapy review |
| url | http://www.cjcnn.org/index.php/cjcnn/article/view/2092 |
| work_keys_str_mv | AT hongyuliu theapplicationofdendriticcellsvaccinationinmalignantglioma AT shaopingshen theapplicationofdendriticcellsvaccinationinmalignantglioma AT linyang theapplicationofdendriticcellsvaccinationinmalignantglioma AT xinguangyu theapplicationofdendriticcellsvaccinationinmalignantglioma AT lingchen theapplicationofdendriticcellsvaccinationinmalignantglioma AT hongyuliu applicationofdendriticcellsvaccinationinmalignantglioma AT shaopingshen applicationofdendriticcellsvaccinationinmalignantglioma AT linyang applicationofdendriticcellsvaccinationinmalignantglioma AT xinguangyu applicationofdendriticcellsvaccinationinmalignantglioma AT lingchen applicationofdendriticcellsvaccinationinmalignantglioma |